AMRI has entered a multi-year drug substance manufacturing agreement with New River Pharmaceuticals, Inc. Under the agreement, AMRI will manufacture the API in New River’s compound, NRP104, a treatment for attention deficit hyperactivity disorder (ADHD) that is currently under review with the FDA. AMRI participated with New River in the development of the chemical process to manufacture NRP104. Financial terms were not disclosed.

“AMRI is delighted to continue its relationship with New River Pharmaceuticals,” said AMRI chairman, president and chief executive officer Thomas E. D’Ambra, Ph.D. “We are well positioned to manufacture this compound based on our long history of manufacturing, as well as our strength in chemical development. Our expertise and specialized capabilities in the area of active ingredient manufacturing provide a unique and value-added capability to AMRI customers.”

Krish Krishnan, New River’s chief financial officer and chief operating officer, commented, “We are confident that AMRI is a solid choice for manufacture. AMRI has the current capability of delivering a quality product in a timely manner, leading us to conclude that it is the best candidate for manufacturing NRP104 for an expected product launch in the first quarter of 2007.”